Bayer is addressing the systemic risks of diabetes by focusing on the cardio-kidney-metabolic connection. Their primary therapy, finerenone (Kerendia), is a non-steroidal medication that specifically targets the inflammation and scarring (fibrosis) that lead to permanent organ damage. This matters because it provides a dedicated line of defense against chronic kidney disease (CKD) and heart failure in type 2 diabetes, with recent FINE-ONE trial results showing a significant 25% reduction in kidney damage markers for those with Type 1 diabetes as well. By treating the heart and kidneys as an interconnected team, Bayer offers a strategy to slow disease progression and prevent major events like heart attacks, moving beyond glucose control to protect the vital organs most affected by long-term metabolic strain.